ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study
Share Article
Emerging biotech aims to accelerate clinical trial start-up and site engagement with on-demand clinical trial readiness platform
ValenzaBio is deploying Ready to transform the critical phases of study start-up and on-going site engagement for their VB119 study CHARLOTTESVILLE, Va. (PRWEB) April 21, 2021
ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study.
ValenzaBio is deploying Ready to transform the critical phases of study start-up and on-going site engagement for their VB119 study. With Ready, ValenzaBio will avoid the typical delays that impede 85% of all clinical trials by